A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
Clinical Cancer Research2010Vol. 16(21), pp. 5222–5232
Citations Over TimeTop 1% of 2010 papers
Torsten O. Nielsen, Joel S. Parker, Samuel Leung, D. Voduc, Mark Ebbert, Tammi L. Vickery, Sherri R. Davies, Jacqueline Snider, Inge J. Stijleman, Jerry P. Reed, Maggie C.U. Cheang, Elaine R. Mardis, Charles M. Perou, Philip S. Bernard, Matthew J. Ellis
Abstract
The PAM50 gene expression test for intrinsic biological subtype can be applied to large series of formalin-fixed, paraffin-embedded breast cancers, and gives more prognostic information than clinical factors and IHC using standard cut points.
Related Papers
- → ESR1 and PGR Gene Promoter Methylation and Correlations with Estrogen and Progesterone Receptors in Ductal and Lobular Breast Cancer(2014)8 cited
- Interobserver reproducibility of immunocytochemical estrogen- and progesterone receptor status assessment in breast cancer.(1996)
- Expressions of estrogen receptor,progesterone receptor and human epithelial receptor-2 in elderly breast cancer patients and their clinical significance(2013)
- → Expression of estrogen receptor and progesterone receptor in different tumor tissues of invasive ductal carcinoma of breast(2011)
- → 5 INVITED Biological roles of PI 3-kinase isoforms(2008)